Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
Executive Summary
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.
You may also be interested in...
Coronavirus Notebook: Australia ‘Recognizes’ Unapproved Vaccines, Russia Bigs Up Sputnik’s Chances At WHO
England’s NICE has given its backing to the use of Regeneron’s Ronapreve, and the UK’s new health security body is now fully up and running.
Pugatch: Pandemic Has Shown IPR-Based System Is Working
Pugatch Consilium managing director, Meir Perez Pugatch, says that IP has been the “bridge” in the various biopharma R&D collaborations that have helped deliver unprecedented results during the pandemic. He also weighs in on the divisive proposal of waiver of intellectual property rights for vaccines, treatments and diagnostics relating to COVID-19.
CureVac Still Hopes Variants Could Win Favor For COVID-19 Vaccine
Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.